|Chemical and physical data|
|Molar mass||349.4713 g/mol|
|3D model (JSmol)|
|(what is this?)|
AL-LAD, also known as 6-allyl-6-nor-LSD, is a psychedelic drug and an analog of lysergic acid diethylamide (LSD). It is described by Alexander Shulgin in the book TiHKAL (Tryptamines i Have Known And Loved). It is synthesized starting from nor-LSD as a precursor, using allyl bromide as a reactant.
Effects in humans
While AL-LAD has subtly different effects than LSD, and appears to be slightly shorter lasting, their potencies are similar; an active dose of AL-LAD is reported to be between 50 and 150 micrograms. AL-LAD has a known but short and highly uncommon history of recreational human use, which originated in Ireland and the UK, but spread internationally.
AL-LAD does not cause a color change with the Marquis, Mecke or Mandelin reagents, but does cause the Ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.
AL-LAD is illegal in Denmark.
AL-LAD is possibly illegal in Latvia. Although it isn't specifically scheduled, it may be controlled as an LSD structural analog due to an amendment made on June 1, 2015.
The Riksdag added AL-LAD to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 6-allyl-6-nor-LSD, AL-LAD, and 6-allyl-N,N-dietyl-9,10-didehydroergolin-8-karboxamid.
AL-LAD is illegal in Switzerland.
AL-LAD is illegal in the UK. On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that AL-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
AL-LAD is not scheduled as a controlled substance at the federal level in the United States, but AL-LAD could legally be considered an analog of LSD, in which case, sales or possession with intent for human consumption could be prosecuted under the Federal Analogue Act.
- Simon D. Brandt; Pierce V. Kavanagh; Folker Westphal; Simon P. Elliott; Jason Wallach; Tristan Colestock; Timothy E. Burrow; Stephen J. Chapman; Alexander Stratford; David E. Nichols; Adam L. Halberstadt (June 2016). "Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. PMID 27265891. doi:10.1002/dta.1985.
- Fabrizio Schifano; Laura Orsolini; Duccio Papanti; John Corkery (June 2016). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. Springer International Publishing. pp. 1–30. ISSN 1866-3370. OCLC 643052237. PMID 27272067. doi:10.1007/7854_2016_15.
- Hoffman AJ, Nichols DE; Nichols (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. PMID 4032428. doi:10.1021/jm00147a022.
- Shulgin, Alexander (1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. p. 392. ISBN 0-9630096-9-9.
- Ecstasydata. "EcstasyData.org - AL-LAD (Not sold as ecstasy)". Retrieved 2013-12-25.
- Convention on Psychotropic Substances, 1971
- "Lists of euphoriant substances". The Danish Medicines Agency. September 2015.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts)
- "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.
- ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.
- §1308.11 Schedule I.
- Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary
- Watts, V. J.; Mailman, R. B.; Lawler, C. P.; Neve, K. A.; Nichols, D. E. (1995). "LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9. PMID 7568626. doi:10.1007/BF02245940.
- Niwaguchi, T; Nakahara, Y; Ishii, H (1976). "Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds". Yakugaku Zasshi. 96 (5): 673–8. PMID 987200.
- Robert C. Pfaff, Xuemei Huang, Danuta Marona-Lewicka, Robert Oberlender and David E. Nichols: Lysergamides Revisited. In: NIDA Research Monograph 146: Hallucinogens: An Update. p. 52, 1994, United States Department of Health and Human Services.